All In Biotech

NDA 022056 · Azurity

Prilosec

Omeprazole Magnesium · Oral

Last checked: Nov 20, 2026Latest source record: Jul 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

Mar 20, 2008

Approved uses

2

Original approval plus efficacy supplements

Registered trials

988

158 Phase 3, 48 recruiting

FAERS reports

107,223

75,635 serious, 9,190 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 19, 2024.

PRILOSEC is a proton pump inhibitor (PPI) indicated for the: • Treatment of active duodenal ulcer in adults ( 1.1 ) • Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults ( 1.2 ) • Treatment of active benign gastric ulcer in adults ( 1.3 ) • Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 1 year of age and older ( 1.4 ) • Treatment of erosive esophagitis (EE) due to acid-mediated GERD in patients 1 month of age and older ( 1.5 ) • Maintenance of healing of EE due to acid-mediated GERD in patients 1 year of age and older ( 1.6 ) • Pathologic hypersecretory conditions in adults ( 1.7 ) 1.1 Treatment of Active Duodenal Ulcer PRILOSEC is indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Triple Therapy PRILOSEC in combination with clarithromycin and amoxicillin, is indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults. Dual Therapy PRILOSEC in combination with clarithromycin is indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Among patients who fail therapy, PRILOSEC with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not...

Mechanism: Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H + /K + ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose-related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • PRILOSEC · OMEPRAZOLE MAGNESIUM EQ 2.5MG BASE/PACKET · FOR SUSPENSION, DELAYED RELEASE, ORAL · Prescription
  • PRILOSEC · OMEPRAZOLE MAGNESIUM EQ 10MG BASE/PACKET · FOR SUSPENSION, DELAYED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Omeprazole" as an intervention, any sponsor and status, largest first.

All 988 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • chronic kidney disease29,730
  • acute kidney injury15,183
  • renal failure12,470
  • end stage renal disease8,730
  • renal injury8,229
  • nausea6,242
  • drug ineffective5,971
  • pain5,718
  • fatigue5,633
  • diarrhoea4,967
  • gastrooesophageal reflux disease4,670
  • dyspnoea4,134

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,427
20051,417
20061,783
20071,511
20081,889
20092,696
20103,462
20114,210
20125,934
20133,772
20144,254
20156,756
20166,721
20175,535
201818,057
201917,650
20206,369
20214,941
20222,950
20231,899
20241,569
20251,395
20261,017

Recalls

1 FDA enforcement reports for this application.

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Prilosec (Omeprazole Magnesium)

2024 spending

$3.2M

Beneficiaries

823

3,254 claims

Per beneficiary

$3,928

$15.25 per unit

View as table
YearSpending
2020$2,992,377
2021$3,155,689
2022$3,465,356
2023$3,235,647
2024$3,232,380

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,390 on PubMed

Sponsor: Azurity

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.